Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
作者： Ellin Berman , Maria Nicolaides , Robert G. Maki , Martin Fleisher , Suzanne Chanel
DOI: 10.1056/NEJMOA051140
关键词:
摘要: Background Imatinib mesylate inhibits several tyrosine kinases, including BCR-ABL, the C-KIT receptor, and platelet-derived growth factor receptors α β, all of which are associated with disease. We observed that hypophosphatemia developed in some patients either chronic myelogenous leukemia or gastrointestinal stromal tumors who were receiving imatinib. Methods identified 16 had low serum phosphate levels 8 normal levels, whom performed following biochemical measurements: whole-blood ionized calcium, plasma intact parathyroid hormone, total phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin magnesium, markers bone formation (bone alkaline phosphatase osteocalcin) resorption (N-telopeptide collagen cross-links); urinalysis; creatinine “spot” urine specimens. Results
cshl.edu
sci-hub.se 参考文章(25)
Bruce H. Mitlak, Richard D. Finkelman, Esther L. Hill, Jun Li, Bruce Martin, Tait Smith, Mark D'Andrea, Harry N. Antoniades, Samuel E. Lynch, The effect of systemically administered PDGF-BB on the rodent skeleton. Journal of Bone and Mineral Research. ,vol. 11, pp. 238- 247 ,(2009) , 10.1002/JBMR.5650110213
Laurie Hickey, Catherine M Gordon, Vitamin D deficiency: new perspectives on an old disease Current Opinion in Endocrinology & Diabetes. ,vol. 11, pp. 18- 25 ,(2004) , 10.1097/00060793-200402000-00006
Robert J Tibshirani, Bradley Efron, An introduction to the bootstrap ,(1993)
J�rg Fiedler, Nadine Etzel, Rolf E. Brenner, To go or not to go: Migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF. Journal of Cellular Biochemistry. ,vol. 93, pp. 990- 998 ,(2004) , 10.1002/JCB.20219
Jonathan Halevy, Severe Hypophosphatemia in Hospitalized Patients Archives of Internal Medicine. ,vol. 148, pp. 153- 155 ,(1988) , 10.1001/ARCHINTE.1988.00380010155016
Lala R. Chaudhary, Keith A. Hruska, The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. Journal of Cellular Biochemistry. ,vol. 81, pp. 304- 311 ,(2001) , 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.0.CO;2-U
W. Wiktor-Jedrzejczak, A. Bartocci, A. W. Ferrante, A. Ahmed-Ansari, K. W. Sell, J. W. Pollard, E. R. Stanley, Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 87, pp. 4828- 4832 ,(1990) , 10.1073/PNAS.87.12.4828
Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes, Klaus Lechner, Johan L Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John Shepherd, Bengt Simonsson, Alois Gratwohl, John M Goldman, Hagop Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E Bolton, Renaud Capdeville, Brian J Druker, None, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia The New England Journal of Medicine. ,vol. 348, pp. 994- 1004 ,(2003) , 10.1056/NEJMOA022457
Michele Gottardi, Enzo Manzato, Filippo Gherlinzoni, Imatinib and Hyperlipidemia The New England Journal of Medicine. ,vol. 353, pp. 2722- 2723 ,(2005) , 10.1056/NEJMC052500
R. Hannon, R. Eastell, Preanalytical variability of biochemical markers of bone turnover. Osteoporosis International. ,vol. 11, pp. 30- 44 ,(2000) , 10.1007/S001980070004